of the 12 fetuses subsequently died in utero. The remaining fetuses suffered no morbidity and were alive and well 3 months to 2 years after delivery. The Flecainide is a potent class lc antiarrhythmic drug that is available in the treatment of atrial, junctional, and ventricular arrhythmias.' It acts on the fast sodium channel and slows conduction throughout the conduction system; its greatest effect is on the His bundle. It was effective and apparently safe in babies and children.2 It was also successful for tachycardia in a fetus.3 However, recent reports of an increase in the incidence of sudden death in adults with ventricular extrasystoles on maintainance flecainide treatment after myocardial infarction have led to recommendations that its use is restricted to patients with life threatening arrhythmias. 45 The intrauterine development of a fetal tachycardia and heart failure is certainly a life threatening condition; fetal mortality is reported to be 20-50%.6'
The variety of drugs reported to be useful in the treatment of fetal tachycardias-for example, digoxin, verapamil, quinidine, procainamide, amiodarone, and propranolol-gives some indication of the difficulty of managing these cases successfully.69"0 We used flecainide in a group of 14 patients with fetal tachycardia. We present our results and recommendations for the use of this drug in this condition in the light of increasing concern about its safety.
Patients and methods Fourteen patients presenting consecutively over a two year period with a fetal tachycardia and cardiac failure were treated with flecainide (an oral dose of 300 mg per day given to the mother). The table summarises the data on these patients. In all except patient 14, gross fetal hydrops was evident at presentation. The gestational age ranged from 23 to 36 weeks (mean 31). The rhythm disturbance was atrial flutter in two and supraventricular tachycardia in 12. One fetus had evidence of reduced left ventricular function on cross sectional, M mode, and Doppler evaluation. Congenital heart disease did not underlie the arrhythmia in any patient.
All patients were treated in hospital. Control of the arrhythmia was achieved in seven of 12 compared with 12 of 14 in the present study but the main difference was in the speed of conversion-the mean time to conversion in the former group being 2-3 weeks compared with 48 hours in the flecainide group. Though the mean age at delivery was similar (35 weeks) in the digoxin and verapamil series and in the flecainide series, the main causes of morbidity in our earlier series were related to the complications of prematurity, especially ischaemic bowel disease. Quick control of the rhythm and time for some resolution of the hydrops will result in an infant in better condition at delivery and may even delay the onset of premature labour. It is possible that our current management procedures, such as peritoneal drainage, also contributed to the improved morbidity. Immediate resuscitation of the newborn is easier if tense ascites has been drained-even if just before delivery. Resolution ofhydrops prenatally takes 1-2 weeks after rhythm control even with drainage procedures but the more complete it is before birth the less hazardous will be the postnatal course.
The ability to achieve therapeutic drug concentrations in the fetus quickly and the high rate of responsiveness make flecainide an attractive alternative to other drugs that are less well transferred by the placenta. The speed of achieving conversion allows the drug to be stopped after rhythm control as it was in four cases. In one, the hydrops had completely resolved and the arrhythmia did not recur; in the others there was a recurrence oftachycardia but this was quickly brought under control a second time. Flecainide probably should not be used for atrial flutter because it can increase the ventricular response and therefore increase the heart rate. In the two patients with atrial flutter treated with flecainide, treatment was changed to digoxin after only 2 days in the first patient and in the other patient digoxin had failed to convert or slow the rhythm after 3 weeks with maternal serum concentrations of digoxin at 2 jug/l (patient 1). Some digoxin still present in the fetus may have protected it from adverse effects and potentiated the conversion with flecainide, which occurred within 48 hours.
Thus it is imperative that the type of rhythm disturbance is not treated blindly but is assessed and correctly identified by M mode echocardiography before treatment is started."2 A further attraction of flecainide is that it can be used for ventricular tachycardias. These are much less common prenatally but do occur. '3 Initially we attributed the unexplained death in our series to the cordocentesis procedure, but this patient may have died of an arrhythmia induced by flecainide. We performed fetal blood sampling in the past as part of our protocol for the management of hydropic tachycardic fetuses in order to estimate the blood gases, karyotype the fetus, and monitor drug concentrations. We judged that the information gained from this procedure justified the risk (l-2%)."6 The death of patient 5 led us to question this policy and also to re-examine the criteria for the use of flecainide. Our current policy does not include routine fetal blood sampling.
Flecainide proved to be a useful drug in the management of fetal tachycardias. However, its use should be limited to patients with supraventricular tachycardia and those with at least moderate or severe hydrops. Patients must be carefully selected and monitored. In addition, mothers must be fully informed ofthe risks of treatment. Accurate diagnosis and optimum management depend on treatment by a paediatric cardiologist experienced in the management of arrhythmias and an obstetrician practised in drainage procedures and in obtaining fetal blood samples for blood gas monitoring-for example, where fetal hypoxia is suspected. Use of flecainide is specifically restricted and its role needs to be further assessed in centres where a large database of results can be collected for analysis.
We thank Dr N Rutter for allowing us to include the data from one of his patients in this report. 
